TRV045 is an investigational product and is not yet approved by the FDA. Subjects in both studies referenced in this press release were enrolled outside of the United States, and the studies were not ...

H.C. Wainwright analyst Edward White has reiterated their bullish stance on NYXH stock, giving a Buy rating on November 5. Edward White has ...

Do you suffer from sleep apnea and long for a peaceful night’s sleep and solution to your snoring? Holy Cross Medical Group pulmonologist Ronald Scott, M.D. will speak about Inspire®, an FDA-approved ...

Inspire Medical Systems (NYSE:INSP) shares dipped today on third-quarter results that came in ahead of the consensus forecast ...

Inspire Medical Systems topped Q3 expectations, signaling continued market strength and innovation.

Inspire is increasing its full year 2024 revenue guidance to between $793 million to $798 million, which represents growth of 27% to 28% over full year 2023 revenue of $624.8 million. This compares to ...

LLY’s slashed revenue and earnings guidance for 2024 were a surprise, especially given substantial raises to its outlook ...

Qsymia’s manufacturer also released postmarketing data showing the oral therapy for weight loss was associated with ...

Among potential surgeries for sleep apnea is UPPP (uvulopalatopharyngoplasty) surgery, which involves removing part of the ...